^
Association details:
| Biomarker: | WNK1-ROS1 fusion + ROS1 G2032R |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib
Excerpt:
When disease progressed, ROS1 G2032R mutation-a classical mechanism of crizotinib resistance-was detected in the DNA sample extracted from the patient's plasma sample....We identified a novel WNK1-ROS1 fusion that was sensitive to crizotinib and developed an ROS1 G2032R mutation when the disease progressed.
DOI:
10.1016/j.lungcan.2018.12.011
